Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bonus BioGroup Ltd. (BONS.TA)
Haifa, IL
Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses. The company's innovation pipeline encompasses bone augmentation treatments for individuals with osteoporosis, cutting-edge nano-materials for drug delivery systems, and advancements in vascularized bone and soft tissue grafts. Originally known as Oceana Advanced Industries Ltd., the company was founded in 1981 and operates from Haifa, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-53.8% Q2'25: +100.0% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-753.0% Q2'25: -364.3% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%-42.7% ★ Q2'25: -40.2% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45× Q2'25: -0.44× (vs Q2'24)
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shai Meretzki | Founder, Chief Executive Officer, President & Director | 543.0K | — |
| Joseph Rauch | Executive Chairman of the Board | 410.0K | male |
| Dror Ben David | Chief Operations Officer | 162.0K | — |
| Meital Enbar | Chief Financial Officer | 110.0K | female |
| Tomer Bronshtein | Vice President of Innovation & Corporate Development | — | — |
| Vered Kivity | Head of Regulatory Affairs & Vice President of Clinical Affairs | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BONS.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
